Menarini group and radius health submit new drug application to the u.s. fda for elacestrant

Florence, italy and boston, june 22, 2022 (globe newswire) -- the menarini group (“menarini”) and radius health, inc. (“radius”) (nasdaq: rdus) (collectively, the “companies”) announced that menarini, with support from radius, has submitted a new drug application (nda) to the u.s. food and drug administration (fda) for elacestrant in patients with er+/her2- advanced or metastatic breast cancer.
RDUS Ratings Summary
RDUS Quant Ranking